Skip to content

Total Equity at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$68.32M-44.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$408.73M-30.8%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$456.23M-35.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$576.22M+4,094%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$1.54B+95.8%
Alumis Inc. logo
Alumis Inc.ALMS
$567.02M+237%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+269%
Enterprise value$700.21M+188%
P/S159.6×+89.0×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's total equity?
DBV Technologies (DBVT) reported total equity of $207.9M in Q1 2026.
How has DBV Technologies's total equity changed year-over-year?
DBV Technologies's total equity increased by 7069.0% year-over-year, from $2.9M to $207.9M.
What is the long-term trend for DBV Technologies's total equity?
Over 5 years (2020 to 2025), DBV Technologies's total equity has grown at a -3.9% compound annual growth rate (CAGR), from $205.49M to $168.8M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.